A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Insulin resistance and aging == Insulin resistance normally increases with ageing in human adults, whereas insulin sensitivity is maintained in centenarians and familial human longevity. Greater longevity in shorter men is associated with reduced insulin resistance. Chronic systemic inflammation increases with aging in human adults, and is associated with many aging-associated diseases. A vicious circle exists between aging and chronic inflammation.
== Plot == As the Federation Starship Enterprise approaches the planet Omega IV, the USS Exeter is found orbiting it. Captain Kirk, First Officer Spock, Dr. McCoy and Lt. Galloway beam over to the Exeter to investigate. They find the ship deserted, save for a few uniforms that are covered with a crystalline substance found to be human remains. The ship's logs reveal that the Exeter's crew died from an infectious disease that had been brought from the planet, and that Enterprise's landing party is now infected and must beam down to the planet if they are to survive. Kirk's party beams down to the last coordinates stored in the Exeter's computer. There, they discover Exeter Captain Ron Tracey (Morgan Woodward). Tracey explains that he had been on the planet when the disease had ravaged his ship, stranding him. He says he has discovered that remaining on the planet confers immunity to the disease. He then reveals that the villagers he is living with on the planet, known as "Kohms", are at war with "savages" called "Yangs". After a Yang attack, Spock investigates the field of battle and finds evidence that Tracey has been helping the Kohms, in violation of the Prime Directive. Kirk tries to contact the Enterprise, but is prevented by Tracey, who tries to justify his violation by revealing that the planet’s natives are not only immune to the mysterious disease, but have also developed lifespans of over 1000 years. Tracey orders McCoy to investigate the secret of their longevity and has Kirk and Spock locked up in a crude jail with two Yang prisoners, one male and one female.
In 2017, Ice-T signed a petition to Congress for criminal-justice reform. His 1994 book, The Ice Opinion, was largely focused on his view on politics. Writing in the aftermath of the 1992 Los Angeles riots, he was one of the only rappers who criticized the targeting of Koreans by some Black rioters. On June 5, 2008, Ice-T joked that he would be voting for John McCain in the 2008 American elections, speculating that his past affiliation with Body Count could hurt Barack Obama's chances if he endorsed him, so he would choose instead to ruin McCain's campaign by saying he supported him. In 2015, Ice-T said that he admired Obama "just for the simple fact he took the shot and went all the way to be president" and included Obama in the list of people who he would like to have for a dream dinner party. On September 22, 2022, Ice-T narrated an advertisement for the Foundation for Individual Rights and Expression.
=== Brady === In February 2019, the trial of Mikel Brady was scheduled for October 7, 2019, making Brady the first of the four set to stand trial for the 2017 prison attack. On October 21, 2019, Brady was found guilty of all four counts of first degree murder and ten other lesser charges, including attempted escape, assault with a deadly weapon and arson. The offence of first degree murder carries a sentence of either life imprisonment without the possibility of parole or the death penalty under North Carolina state law. During the sentencing trial, the defence argued for Brady to be sentenced to life imprisonment, citing the details of Brady's troubled childhood and past medical history of his psychiatric conditions. Brady's lawyer, Thomas Manning, summarized Brady's childhood into a poem, "As the twig is bent, so goes the tree". On the other hand, the prosecution sought the death penalty, with District Attorney Andrew Womble citing the brutality of the attack and aggravating factors in the case. Womble also quoted that if the jury settled on life imprisonment, "it will be open season on corrections officers in this state." On October 28, 2019, 30-year-old Mikel Brady was sentenced to death upon the jury's unanimous recommendation for capital punishment, making Brady the 143rd inmate to be condemned to death row in North Carolina; a total of 142 inmates were held on death row in North Carolina at the time of Brady's sentencing. After he was sentenced to death, Brady was at first held on death row at the Central Prison in Raleigh, North Carolina.
Sources: en.wikipedia.org
binary fission The separation of a single entity (e.g. a cell) into exactly two discrete entities closely resembling the original. The term refers in particular to a type of cell division used by prokaryotes such as bacteria, whereby a single parent cell divides evenly into two daughter cells which are genetically identical to each other and to the parent. Binary fission is preceded by replication of the parent cell's DNA, rapid growth of the cell wall, and various other processes which ensure even distribution of the cell's contents between the two progeny, but is generally a quicker and simpler process than the mitosis and cytokinesis that occur in eukaryotes.
Under these conditions, if the pathogenic mutation arises after a compensatory mutation, then P can become fixed in the population. The second model of CPDs states that P and C are both deleterious mutations resulting in fitness valleys when mutations occur simultaneously. Using publicly available, Ferrer-Costa et al. 2007 obtained compensatory mutations and human pathogenic mutation datasets that were characterized to determine what causes CPDs. Results indicate that the structural constraints and the location in protein structure determine whether compensated mutations will occur.
=== Reading room === The original Reading Room was founded in August 1935 to entertain unemployed workers during the Great Depression. Started as an initiative by the New York Public Library, the Reading Room provided the jobless with a place to interact and share ideas without having to pay money or show identification. Despite this, the library was well-used, being used by 50,000 people by its first anniversary. Theft was low, with only 34 publications being lost in the library's first year. By its third year, 400 books and 1,000 magazines were in circulation and were being perused by 70,000 people per year. Books from the NYPL, and donations of magazines and trade publications from publishers, contributed to the success of the open-air library. The tradition of Reading Rooms halted in 1944 due to a staff shortage during World War II. The Reading Room tradition was revived in 2003 with HSBC as its first sponsor. Oxford University Press, Scholastic Corporation, Mitchell's NY, Condé Nast Publications, Time Inc., Hachette Filipacchi Media U.S., and Rodale, Inc. were among the companies who donated books and publications. In addition to the complimentary reading materials, in 2004 programming was added to Reading Room's content. The Reading Room features readings and book sales by contemporary writers and poets, plus book-related special events such as book clubs, writers workshops and storytelling for kids.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.